Defects in the vasoactive intestinal peptide (VIP)/VPAC system during early stages of the placental-maternal leucocyte interaction impair the maternal tolerogenic response.
about
VIP treatment prevents embryo resorption by modulating efferocytosis and activation profile of maternal macrophages in the CBAxDBA resorption prone modelTolerance induction at the early maternal-placental interface through selective cell recruitment and targeting by immune polypeptides.VIP boosts regulatory T cell induction by trophoblast cells in an in vitro model of trophoblast-maternal leukocyte interaction.Tissue transglutaminase on trophoblast cells as a possible target of autoantibodies contributing to pregnancy complications in celiac patients.Effect of baicalein on the expression of VIP in extravillous cytotrophoblasts infected with human cytomegalovirus in vitro.
P2860
Defects in the vasoactive intestinal peptide (VIP)/VPAC system during early stages of the placental-maternal leucocyte interaction impair the maternal tolerogenic response.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Defects in the vasoactive inte ...... maternal tolerogenic response.
@en
Defects in the vasoactive intestinal peptide
@nl
type
label
Defects in the vasoactive inte ...... maternal tolerogenic response.
@en
Defects in the vasoactive intestinal peptide
@nl
prefLabel
Defects in the vasoactive inte ...... maternal tolerogenic response.
@en
Defects in the vasoactive intestinal peptide
@nl
P2093
P2860
P1476
Defects in the vasoactive inte ...... maternal tolerogenic response.
@en
P2093
C Pérez Leirós
L Fraccaroli
M Cortelezzi
R Ramhorst
P2860
P304
P356
10.1111/J.1365-2249.2012.04668.X
P577
2012-12-01T00:00:00Z